A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Public ClinicalTrials.gov record NCT07549412. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Study identification
- NCT ID
- NCT07549412
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,020 participants
Conditions and interventions
Conditions
Interventions
- Precemtabart tocentecan Drug
- Bevacizumab Drug
- Trifluridine/Tipiracil (FTD-TPI) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2026
- Primary completion
- Oct 15, 2029
- Completion
- Oct 15, 2029
- Last update posted
- Aug 13, 2026
2026 – 2029
United States locations
- U.S. sites
- 18
- U.S. states
- 9
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Centers, LLP- Aurora | Lone Tree | Colorado | 80124 | Recruiting |
| Florida Cancer Specialists-Broadway | Fort Myers | Florida | 33901 | Recruiting |
| Florida Cancer Specialists - St. Petersburg Bayfront | St. Petersburg | Florida | 33701-4553 | Recruiting |
| Florida Cancer Specialists East - FCS EAST - West Palm Beach | West Palm Beach | Florida | 33401 | Recruiting |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | Recruiting |
| Illinois CancerCare PC | Peoria | Illinois | 61615-7822 | Recruiting |
| Springfield Clinic | Springfield | Illinois | 62702 | Recruiting |
| Profound Research LLC at Cancer and Leukemia Center | Sterling Heights | Michigan | 48098 | Recruiting |
| Minnesota Oncology Hematology, P.A. | Saint Louis Park | Minnesota | 55416 | Recruiting |
| Missouri Cancer Associates - 150518964 | Columbia | Missouri | 65201 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology, P.A. - Abilene - 300210366 | Abilene | Texas | 79606 | Recruiting |
| Texas Oncology-South Austin | Austin | Texas | 78745 | Recruiting |
| Texas Oncology DFW | Bedford | Texas | 75246 | Recruiting |
| Texas Oncology- San Antonio | San Antonio | Texas | 78240 | Recruiting |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | Recruiting |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | Recruiting |
| Blue Ridge Cancer Care - 300202915 | Roanoke | Virginia | 24014-2419 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07549412, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07549412 live on ClinicalTrials.gov.